Caris Life Sciences

Caris showcases new findings on the clinical value of subtracting clonal hematopoiesis (CH) mutations from liquid biopsy profiling. This innovative approach helps improve patient treatment recommendations. The study highlights the power of the Caris Assure? assay, which uses a single whole exome & transcriptome sequencing assay to identify somatic tumor, incidental CH and germline variants from both plasma and buffy coat. Learn more:?https://lnkd.in/gQ-ufdnT #CarisAssure #MolecularProfiling #PrecisionMedicine

Caris showcases data highlighting the clinical value of subtracting clonal hematopoiesis (CH) mutations from liquid biopsy profiling results to improve accurate treatment recommendations during the International Society for Liquid Biopsy (ISLB) 6th Annual Congress. “As we age, we accumulate somatic CH mutations in our blood that can lead to clinical false positives in blood-based molecular profiling tests, complicating treatment decisions,” said George Sledge, Jr., MD, EVP and Chief Medical Officer of Caris. “Accurately determining which variants are coming directly from the tumor, versus which are germline or CH, is critical to patient care. This enables oncologists to treat the tumor rather than treating mutations from other sources, lessening the possibility of recommending a treatment that is not appropriate, and potentially harmful, for the patient.”? ? Learn more:?https://lnkd.in/gGj96cfM ? #ISLB24

If you are attending the International Society of Liquid Biopsy Annual meeting in Denver make sure you check out our poster (PP01.05) ‘Characterization of plasma??cfDNA variants ?? as of tumor ?? or CHIP origin in almost 12,000 advanced cancer patients’. Strong ?? work from Daniel Magee and our team at Caris Life Sciences. #ISLB24 #liquidbiopsy #CH #ngs #molecular #profiling #cfDNA #precisionmedicine #OncoDaily #carisls

Join us at ISLB 2024 in Denver. Visit the Caris Life Sciences booth 105 to explore our innovative solutions in precision medicine. Our team is eager to connect, share insights, and discuss how we can advance patient care together. #ISLB24 https://lnkd.in/gvZewVrq

Can combined DNA and RNA sequencing improve the identification of therapeutic targets in glioblastoma (GBM)? Dr. Sonikpreet Aulakh from West Virginia University Cancer Institute will describe a study of 4,392 IDH-wild type GBM where whole transcriptome sequencing identified pathogenic fusion transcripts in almost 10% of cases. https://lnkd.in/ga9tAZ8 #SNO2024

Could liquid biopsy of cerebrospinal fluid (CSF) help identify mutations in primary and metastatic brain tumors? In a preliminary study, Dr. Kyle Tuohy from Penn State’s Hershey Medical Center presents whole exome sequencing (WES) results from 20 cases. https://lnkd.in/ga9tAZ8 #SNO2024

Could TIM3 be a viable target of immunotherapy (IO) in pediatric glioma? Hear Shashwat Tripathi (Shashwat T.) from the Northwestern University - The Feinberg School of Medicine & Lurie Cancer Center discuss how whole transcriptome and single-cell sequencing, mouse models, and flow cytometry point to TIM3 in BRAF-fused MAPK-driven pilocytic astrocytomas. https://lnkd.in/ga9tAZ8 #SNO2024

Caris Life Sciences is pleased to announce the appointment of Dr. Jeff Vacirca, CEO and Chairman of the Board of New York Cancer & Blood Specialists, to our Board of Directors. “We are thrilled to welcome Jeff to our board,” said David Dean Halbert, DSc (h.c.), Chairman, Founder and CEO of Caris. “His extensive leadership across cancer care delivery, therapeutic development and patient/legislative advocacy, as well as his entrepreneurial experience, will bring an invaluable perspective to our board of directors.” Learn more: https://lnkd.in/g6Ti23Ra

Join Jaclyn Hechtman, MD, as she explores the power of whole blood profiling with Caris Assure to distinguish between clonal hematopoiesis (CH) and tumor mutations. By analyzing both plasma and Buffy coat, this approach provides clinicians with the comprehensive molecular intelligence needed to develop treatment plans that may help improve patient outcomes. #AMPath24 https://lnkd.in/gZm92Zdg